42.04
Schlusskurs vom Vortag:
$44.20
Offen:
$43.24
24-Stunden-Volumen:
117.25K
Relative Volume:
0.23
Marktkapitalisierung:
$1.31B
Einnahmen:
$1.32B
Nettoeinkommen (Verlust:
$110.20M
KGV:
11.87
EPS:
3.5417
Netto-Cashflow:
$148.24M
1W Leistung:
+3.95%
1M Leistung:
+8.03%
6M Leistung:
-20.39%
1J Leistung:
-38.74%
Conmed Corp Stock (CNMD) Company Profile
Firmenname
Conmed Corp
Sektor
Branche
Telefon
727-214-2974
Adresse
11311 CONCEPT BOULEVARD, LARGO, NY
Vergleichen Sie CNMD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
CNMD
Conmed Corp
|
42.26 | 1.37B | 1.32B | 110.20M | 148.24M | 3.5417 |
|
ABT
Abbott Laboratories
|
125.48 | 219.41B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
97.78 | 145.84B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
368.17 | 140.43B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
97.59 | 126.52B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
85.14 | 49.08B | 5.88B | 1.34B | 799.60M | 2.3489 |
Conmed Corp Stock (CNMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-12 | Herabstufung | Needham | Buy → Hold |
| 2025-04-28 | Herabstufung | Stifel | Buy → Hold |
| 2025-02-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-02-01 | Bestätigt | Needham | Buy |
| 2023-05-22 | Eingeleitet | CL King | Buy |
| 2023-03-27 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2023-03-21 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2021-10-06 | Hochstufung | Needham | Hold → Buy |
| 2021-07-15 | Eingeleitet | UBS | Buy |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2019-11-26 | Herabstufung | Needham | Buy → Hold |
| 2019-11-12 | Eingeleitet | JP Morgan | Overweight |
| 2019-10-31 | Bestätigt | Needham | Buy |
| 2019-10-04 | Bestätigt | Needham | Buy |
| 2019-08-22 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-04-18 | Eingeleitet | Stifel | Buy |
| 2019-04-16 | Bestätigt | Needham | Buy |
| 2019-01-23 | Bestätigt | Needham | Buy |
| 2018-10-16 | Eingeleitet | Barclays | Equal Weight |
| 2018-08-07 | Bestätigt | Needham | Buy |
| 2018-08-02 | Bestätigt | Needham | Buy |
| 2018-04-26 | Bestätigt | Needham | Buy |
| 2018-02-01 | Bestätigt | Needham | Buy |
| 2017-07-27 | Bestätigt | Needham | Buy |
| 2017-04-27 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2017-04-27 | Bestätigt | Needham | Buy |
| 2016-11-18 | Bestätigt | Needham | Buy |
| 2016-07-28 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
| 2016-04-28 | Bestätigt | Needham | Buy |
| 2015-10-22 | Bestätigt | Northland Capital | Market Perform |
Alle ansehen
Conmed Corp Aktie (CNMD) Neueste Nachrichten
CONMED CFO Todd Garner to step down in March 2026 - Investing.com
CONMED Corp Announces CFO Transition - TradingView — Track All Markets
CONMED (NYSE: CNMD) details CFO Todd Garner’s exit terms and transition plan - Stock Titan
CONMED changes its finance chief but keeps 2025 goals on track - Stock Titan
Tech Rally: What technical signals suggest for CONMED Corporation stockCPI Data & Target Return Focused Picks - ulpravda.ru
CONMED (CNMD) EVP Brent Lalomia reports 401(k) share acquisitions - Stock Titan
Tributary Capital Management LLC Acquires Shares of 415,672 CONMED Corporation $CNMD - MarketBeat
CONMED Corporation (NYSE:CNMD) Receives Average Recommendation of “Reduce” from Analysts - Defense World
CONMED Corporation (NYSE:CNMD) Receives Average Recommendation of "Reduce" from Analysts - MarketBeat
Here's why you should retain CONMED stock in your portfolio now - MSN
Is There An Opportunity In CONMED (CNMD) After A 38% One Year Share Price Fall - simplywall.st
CONMED leaders to share company update at J.P. Morgan Healthcare Conference - Stock Titan
What CONMED’s Jan. 28 earnings call could reveal about 2025 - Stock Titan
CONMED (NYSE:CNMD) Cut to Strong Sell at Zacks Research - Defense World
CONMED (NYSE:CNMD) Rating Lowered to Strong Sell at Zacks Research - MarketBeat
Investor Mood: Why CONMED Corporation stock could rally strongly2025 Key Highlights & Daily Market Momentum Tracking - moha.gov.vn
Here's Why You Should Retain CONMED Stock in Your Portfolio Now - Finviz
Why Conmed (CNMD) is a Top Value Stock for the Long-Term - Yahoo Finance
Is There Now An Opportunity In CONMED Corporation (NYSE:CNMD)? - Yahoo Finance
Why CONMED Corporation stock could rally in 2025Forecast Cut & Proven Capital Preservation Methods - Улправда
Will CONMED Corporation stock outperform Nasdaq indexJuly 2025 Drop Watch & High Accuracy Swing Entry Alerts - Улправда
Published on: 2025-12-19 14:29:06 - DonanımHaber
Will Exiting Gastroenterology to Refocus on Core Surgery Change CONMED’s (CNMD) Margin Expansion Narrative? - simplywall.st
Is CONMED Corporation stock near bottom after declineJuly 2025 Analyst Calls & Trade Opportunity Analysis - Улправда
Why CONMED (CNMD) Stock Is Trading Up Today - Finviz
CONMED (CNMD) Valuation Review as It Exits Gastroenterology and Refocuses on Core Growth Areas - simplywall.st
Here's Why Conmed (CNMD) is a Strong Growth Stock - Yahoo Finance
Here's Why Conmed (CNMD) is a Strong Value Stock - Yahoo Finance
Oversold Conditions For CONMED (CNMD) - Nasdaq
CONMED (NYSE:CNMD) Price Target Lowered to $52.00 at Bank of America - Defense World
CONMED (NYSE:CNMD) Shares Little Changed After Operations Update - Kalkine Media
CONMED Stock Falls as It Strategically Exits Gastroenterology Portfolio - Yahoo Finance
Conmed to exit gastroenterology business - Yahoo Finance
Is CONMED (CNMD) Trading Niche Biliary Devices For A Higher-Margin Endoscopy Future? - Yahoo Finance
Looking at the Narrative for CONMED After Analyst Model Tweaks and Capital Moves - Yahoo Finance
How Conmed Corp.Ordinary Shares (CNMD) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Here's why you should add CONMED stock to your portfolio now - MSN
CONMED (NYSE:CNMD) Hits New 52-Week LowWhat's Next? - MarketBeat
CONMED (CNMD) Passes Through 2% Yield Mark - Nasdaq
CONMED to Exit Gastroenterology Market - Medical Product Outsourcing
CONMED to exit gastroenterology product lines as part of portfolio shift - Medical Economics
Why CONMED (CNMD) Shares Are Plunging Today - Finviz
Conmed stock hits 52-week low at 40.0 USD - Investing.com
Why Is Conmed (CNMD) Up 0.1% Since Last Earnings Report? - Yahoo Finance
Why Is Conmed Stock Falling Friday?Conmed (NYSE:CNMD) - Benzinga
Conmed to exit gastroenterology product lines, transfer Gore Viabil rights to Olympus - MassDevice
Conmed to conclude distribution agreement with W. L. Gore & Associates - TipRanks
Conmed to Exit Gastroenterology Product Lines, End Distribution Deal With Gore - marketscreener.com
Conmed to exit gastroenterology business, ends Gore distribution deal - Investing.com
Conmed to exit gastroenterology business, ends Gore distribution deal By Investing.com - Investing.com Canada
Conmed Exits Gastroenterology Products to Focus on Core Markets - TipRanks
Finanzdaten der Conmed Corp-Aktie (CNMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):